Index

Acute retroviral syndrome (ARS), 143–144
Adult AIDS Clinical Trials Group (AACTG)
  Annual Report
    computer-based survey, 254
    participation percentage, 245–246
    treatment, 246
African-Americans, epidemiology
  AIDS proportions, 3
  HIV annual death rates, 4
  HIV infection
    black adolescents, 7–8
    black men who have sex with men, 5–7
    black women, 5
    Hispanic women, 5
    multiple sexual partners, 9
    non-Hispanic blacks, 11
    positive test, 5
  substance abuse, 10
AIDS drug assistance program (ADAP), 9
AIDS Education and Training Center (AETC), 13
American Medical Association (AMA), 250
Amyotrophic lateral sclerosis (ALS), 7
Antiretroviral pregnancy registry (APR), 108, 109, 113
Antiretroviral therapy, 2
  adherence, 115
  efavirenz (EFV), 34–36
  fixed-dose dual nucleoside/nucleotide analogue backbone
    abacavir plus lamivudine, 38
    tenofovir plus emtricitabine, 38–39
    zidovudine plus lamivudine, 40
  maternal and fetal safety
    mitochondrial toxicities, 114
    trimester exposure, 113–114
  ZDV monotherapy, 114–115
neonatal safety, 115
  ritonavir-boosted protease inhibitor, 33
  unified global HIV prevalence
    adherence, 291–292
    scale-up, 290
Antiretroviral treatment and access study (ARTAS), 72
Artificial insemination, 123
Assisted reproductive technologies (ART), 123
AZT induced melanonychia, nail disorder, 153
  Boosted protease inhibitor, 36–38. See also
    Ritonavir-boosted protease inhibitor
  CCR5 inhibitor, HIV treatment, 45–46
Centers for Disease Control and Prevention (CDC), 24, 41, 105, 113, 223
  “call to action” documents, 12
  Heightened National Response Initiative, 15
  HIV
    infection diagnosis, 70
    testing, 71
  prevention service expansion, 13
Childhood sexual abuse (CSA), 191
CIDI. See Composite International Diagnostic Interview survey
Clinical staff diversification, 59
Clinical trials, African-Americans
  barriers
    beliefs and perceptions, 251–252
    distrust issues, 255
    eligibility criteria, 256
    health care disparity, 252
    human subject protection, 253–254
    lack of education, 253
    medical establishment, 248
    medical schools, 249–250
poverty, 253
recruitment and enrollment, 254
slave medicine, 248–249
syphilis study, 250
myths and conspiracy beliefs, 252
participation
cancer research trials, 247–248
disadvantages, 246
immediate vs. delayed zidovudine therapy, 246
initial therapy LPV/r plus efavirenz, 247
triple nucleoside regimen vs. efavirenz, 246–247
strategies
community oriented research, 256
community partner, 257
honoraria, 257
recruitment, 254
value of research, 257
under-representation, 245
Community Programs for Clinical Research on AIDS, 256
Comorbidities, HIV-infected African-Americans
anemia, 167–168
cardiovascular disease
Framingham risk score, 167
myocardial infarction, 166
oral glucose tolerance testing, 167
diabetes and metabolic syndrome
abnormal glucose metabolism, 169
diabetes mellitus, 170
hepatitis C virus (HCV) infection, 159–160
lipodystrophy
clinical manifestation, 168
lipoatrophy and lipo hypertrophy, 169
obesity, 169
renal disease
end-stage renal disease, 170
HIV associated nephropathy (HIVAN), 171
renal biopsy, 171
risk factors, 170
Composite International Diagnostic Interview survey, 232
Comprehensive AIDS Resources Emergency Act (CARE Act), 13
Condylomata lata, 137, 139
CPCR A. See Community Programs for Clinical Research on AIDS
Crusted scabies
diagnosis, 149
sarcopites scabei var hominis, 148
Cryosurgery, 146. See also Liquid nitrogen therapy
Culturally competent HIV care
access to, 70
definition, 69
drug treatment, 71
hospitalization, 70
infusion, 71
individual-level services, 70
restrictions, 70
services provided, 70
training, 71
under-representation, 70
Community Programs for Clinical Research on AIDS (CPCR A)
Comprehensive AIDS Resources Emergency Act (CARE Act), 13
Condylomata lata, 137, 139
CPCR A. See Community Programs for Clinical Research on AIDS
Crusted scabies
diagnosis, 149
sarcopites scabei var hominis, 148
Cryosurgery, 146. See also Liquid nitrogen therapy
Culturally competent HIV care
access to, 70
definition, 69
drug treatment, 71
hospitalization, 70
infusion, 71
individual-level services, 70
restrictions, 70
services provided, 70
training, 71
under-representation, 70
Community Programs for Clinical Research on AIDS (CPCR A)
Comprehensive AIDS Resources Emergency Act (CARE Act), 13
Condylomata lata, 137, 139
CPCR A. See Community Programs for Clinical Research on AIDS
Crusted scabies
diagnosis, 149
sarcopites scabei var hominis, 148
Cryosurgery, 146. See also Liquid nitrogen therapy
Culturally competent HIV care
access to, 70
definition, 69
drug treatment, 71
hospitalization, 70
infusion, 71
individual-level services, 70
restrictions, 70
services provided, 70
training, 71
under-representation, 70
Community Programs for Clinical Research on AIDS (CPCR A)
Comprehensive AIDS Resources Emergency Act (CARE Act), 13
Condylomata lata, 137, 139
CPCR A. See Community Programs for Clinical Research on AIDS
Crusted scabies
diagnosis, 149
sarcopites scabei var hominis, 148

nail disorders, 153
post inflammatory pigmentary alteration, 154–155
skin disease chronology, 135
viral infections
  acute retroviral syndrome (ARS), 143–144
  herpes simplex virus (HSV) infection, 147
  herpes zoster infection, 147–148
  human papilloma virus infection, 144–145
  mollusca contagiosa, 145–146
Dermatophytes
  clinical diagnosis, 142
  erythematous, 141
  superficial fungal infection, 141
tinea incognito, 142
DHHS. See Department of Human Health Services
Diffusion of evidence-based effective behavioral interventions (DEBI), 195
Diffusion of evidence-based intervention program, 223
Disease progression, 6
Drug use, 9
Efavirenz (EFV)
  advantages and disadvantages, 35, 36
  CNS toxicity, 35
  GI side effects, 34
  one pill per day regimen, 34
  reproductive risk potential, 35
  reverse transcriptase enzyme, 35
tolerability, 35
Enhanced perinatal surveillance report, 105
Epidemiology, HIV women
  clinical care, 94–95
  contraception
    barrier contraception, 92
    hormonal contraception, 92–93
    injectable contraception, 93
gynecologic issues and clinical manifestations
  bacterial vaginosis, 89
  candidal vaginal infection, 90
cervical cytologic abnormalities, 91–92
gonorrhea and chlamydia, 90
  herpes simplex virus infection, 90–91
  human papilloma virus infection, 91–92
  syphilis, 90
  trichomonas vaginalis, 89
natural history, 86–87
non-gynecologic manifestations
  hematologic complications, 88
  Kaposi’s sarcoma, 87–88
  pneumocystis pneumonia (PCP), 88
  older woman, menopause, 93–94
  risk factors
    heterosexual transmission, 84
    hormonal contraception, 92–93
    injection drug use (IDU), 84–85
    sexual intercourse during menstruation, 86
Federal poverty level (FPL), 3
Fos-amprenavir (FPV/r), 37
HAART. See Highly active antiretroviral therapy
Health care
  African-Americans, 16
  Latino population, 28
  US minorities, 56
Health insurance, African-Americans, 8–9
Health literacy
  Latino population, 28
  readiness assessment, 61
Hepatitis C virus (HCV) infection
  end-stage liver disease (ESLD), 159
  hepato-cellular carcinoma (HCC), 160
  HIV–HCV coinfection, 160–161
  treatment and outcomes
    cytokine production, 165
    early virologic response (EVR), 162
    HCV RNA testing, 162
    host factors, 164
    new agents, 165–166
    pegylated interferon (IFN) and ribavirin, 163, 164
    sustained virologic response (SVR), 162
    viral factors, 164–165
  treatment eligibility, 161–162
Herpes simplex virus (HSV) infection
  ethnic minority populations, 147
  Kaposi’s sarcoma (KS), 152
  risk factors, 147
Heterosexual African-American women
  HIV prevention interventions
    crack cocaine usage, 219
    dissemination, 223
    sistas, informing healing, living and empowering (SIHLE), 222
    three-arm trial, out-of-drug treatment, 222
    unsafe sexual practices, 218–219
  women involved in life learning from other women (WILLOW), 221
HIV-related exposures and risk factors, 222
HIV risk reduction agenda, 224–225
theoretical frameworks
  sexual division of labor, 215–217
  sexual division of power, 217
social health of African-American women (SHAWL), 214
structure of cathexis, 218
theory of gender and power, 215, 216, 218
Highly active antiretroviral therapy (HAART), 5, 94–95, 159, 162, 167–168, 170
intrapartum diagnosis, 111
long term survivors, 121–122
lost life expectancy years, 55
patient adherence, 60–61
pregnancy treatment, 110–111
preterm delivery (PTD), 117
race effect, 43–45
race/ethnicity disparity, 54
readiness assessment
depression evaluation, 61–62
health literacy, 61
substance abuse, 61
treatment challenges
coinfection, 290
opt-out testing strategy, 295
skilled human resources, 290–291
vaccine development, 295
virologic failure, 42–43
HIV associated nephropathy (HIVAN), 171
HIV Cost and Services Utilization Study (HCSUS), 229, 253
HIV outpatient study (HOPS), 54
HIV prevention interventions,
African-American women
crack cocaine usage, 219
dissemination, 223
sistas, informing healing, living and empowering (SIHLE), 222
three-arm trial, out-of-drug treatment, 220
unsafe sexual practices, 218–219
women involved in life learning from other women (WILLOW), 221
HIV risk reduction strategies, drug using population
accessible treatment and services, mental health issues, 236
benefits, social support, 236–237
community-based outreach, 233
drug treatment, 233–234
network-based interventions, 234–235
HLA-B*5701, histocompatibility antigen, 39
HSV-2 infection. See Herpes simplex virus infection
Human papilloma virus (HPV) infection
abnormal cervical Pap smear management, 91
hyperplasia, 144
oral warts, 145
squamous cell carcinoma (SCC), 145
vulvar intraepithelial neoplasia (VIN), 92
Hyperensitivity reaction (HSR), abacavir, 39–40
IDU. See Injection drug users
Immune reconstitution syndrome (IRS), 154
Initial therapy LPV/r plus efavirenz, 247
Injectable contraception, 93
Injection drug users
HIV risk reduction intervention, 233–234
needle exchange program, 275
prevalence, 228–229
Institutional review board (IRB), 254
Integrase inhibitor, antiretroviral agent, 46
Integrated treatment
dual and triple diagnosis
ancillary services, 239
barriers, 239
effectiveness, 238
mental health and substance abuse, 238
model, 238–239
multiple service delivery system, 237–238
mental illness, 232
Intracytoplasmic sperm injection (ICSI), 123
Intravenous drug use (IDU), 288
In vitro fertilization (IVF). See Intracytoplasmic sperm injection (ICSI)
Kaposi’s sarcoma (KS), 87–88, 152
Latino population, epidemiology
acculturation levels, 23
care and treatment
antiretroviral therapy, 27
cultural barriers, 29
gender barriers, 27
language barriers, 28
sexual norms, 27
socio-economic barriers, 23
ethnic characteristics, 23
HIV infection
diagnosis, 24, 25
reports, 26
risk factor, 26–27
HIV transmission methods
heterosexual contact, 25
injection drug use (IDU), 25
migration patterns, 28
prevention services
condom use, 27
health care and literacy, 28
HIV testing, 29
Lesbian gay and bisexual (LGB) community, 202
Liaison Committee on Medical Education (LCME), 76
Lipodystrophy syndrome clinical manifestation, 168
facial lipoatrophy, 153
injectable volume replacement fillers, 154
lipoatrophy and lipohypertrophy, 168, 169
Liquid nitrogen therapy, 146

Macrosocial factors
definition, 215
role, 214–215, 217
theory of gender and power refinement, 217
MAI. See Minority AIDS Initiative
Male circumcision
decreased HIV transmission risk, 288
dissemination challenges, 290
Many Men, Many Voices intervention. See 3MV intervention
Medicaid insurance, 72
Medicaid program
dual eligibles, 266
eligibility criteria, 264
limitation, 264
services, 264
treatment, 265
Medicare program
benefits, 267–270
eligibles, 269
federal spending, 267
problems, 270–271
summary, 268
Men who have sex with men (MSM)
AIDS case reports, 6
community level interventions
Creating Responsible Intelligent Black Brothers (CRIBB), 199
The Love Ball, 199
Pride in the City (PITC), 198–199
diagnosis rate, 6
disease progression, 6–7
epidemic, 287–288
formative research
Asian/Pacific islander (API), 187
black MSM, 188–189
Latino MSM, 189–190
health disparities
epistemological-theoretical framework, 184
interdisciplinary and intersectional theory, 184–185
partner counseling and referral services (PCRS), 200
HIV infection rates, 289
HIV prevention
assessment, 194
evidence-based standards, 196
house ball communities, 185, 199
immigration influence, 192–193
marginalization, 181–182
political factors, 182, 183
socio-economic status (SES), 182
stigmatization, 202, 203
structural inequalities, 181–182
syndemic theoretical conceptualizations, 183–184
violence experiences, 191
intravenous drug use, 288
Mpowerment project, 198
psychosocial support and mental health needs
racial/ethnic discrimination, 201
sociocultural factors, 202–203
public health, 181–184
revised HIV testing, 200–201
risk factors, 289
crystal methamphetamine, 192
social oppression, 185–186
substance use, 191–192
unprotected anal intercourse (UAI), 186
sexual contexts and networks, 190–191
stigma and discrimination, 287
Minority AIDS Initiative (MAI), 273
Mollusca contagiosa
clinical diagnosis, 146
liquid nitrogen therapy, 146
pox virus, 145
Mortality, 3
Mother-infant rapid intervention at delivery study (MYRIAD), 112
Mother to child transmission (MTCT) prevention, 107–112
MSM. See Men who have sex with men
3MV intervention, 195
Naïve patient treatment
darunavir, protease inhibitor, 38
efavirenz (EFV), 34–36
fos-amprenavir, 37
initial regimens, 33, 34
nevirapine, 35–36
tenofovir/emtricitabine, 38–39
zidovudine plus lamivudine, 40
National Health Interview Survey (NHIS), 71
National HIV Behavioral Surveillance (NHBS) system, 6
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 164
National prevention strategy, 292–293
Needle exchange program (NEP) ban, federal funding, 275
injected drug use, 274–275
Nephrotoxicity, tenofovir chronic kidney disease, African-American, 38–39
HIV associated nephropathy (HIVAN), 38
NIH Revitalization ACT, 254
NNRTI based regimens, 35
Non-Hodgkins lymphoma (NHL), 87–88
Norwegian scabies, 149. See also Crusted scabies
Ochronosis, 155
Opt-out testing, 294
Orthotopic liver transplantation (OLT), 161
Partner counseling and referral services (PCRS), 200
Pediatrics AIDS clinical trial group (PACTG) protocol, 109
People living with HIV/AIDS (PLWHA).
See also Medicaid program; Medicare program; Ryan White HIV/AIDS program
barriers, enrollment and care, 278
demography, 261, 262
federal health and national policy, 278
people enrolled, 269
public health programs, 261, 262
People of color in crisis (POCC), 198
PMTCT. See Prevention of mother to child transmission
Pneumocystic carinii pneumonia, 2
Policies and politics, HIV
CDC testing recommendatons, 276
communities of color, 277
federal spending, 262
HIV/AIDS care, 261
Medicaid
dual eligibles, 266
eligibility criteria, 264
limitation, 264
treatment, 265
Medicare
benefits, 267–270
eligibles, 269
federal spending, 267
problems, 270–271
needle exchange program (NEP) ban, federal funding, 275
injected drug use, 274–275
PLWHA, 261–263
Ryan White HIV/AIDS Program autonomy, 271–272
benefits, 272
clinical and technical training, 273
community and consumer involvement, 272–273
funds, 273–274
limitation, 274
Minority AIDS Initiative (MAI), 273
Popular opinion leader (POL) model, 197
Pregnancy, HIV-infected women antiretroviral therapy agents, 107
maternal and fetal safety, 113–114
neonatal safety, 113, 115
nevirapine hepatotoxicity, 114
protease inhibitors, 108
transplacental passage, 108, 109
virologic response, 109
zidovudine (ZDV) monotherapy, 109, 114
complications erythropoietin therapy, 116
gestational diabetes, 118
GLUT4 glucose transport activity, 117
lipid metabolism, 118
preterm delivery (PTD), 117
preterm premature rupture of membranes (PPROM), 116
thrombocytopenia, 116
conservative management, 117
diagnosis and characteristics counseling and testing, 104
mother to child transmission (MTCT), 105–107
seroconversion, 104
hepatitis C infection, 122
laboratories and assessment, 105, 106
older pregnant women, 121
perinatally infected adolescents, 120–121
perinatal transmission, 103, 104
prenatal diagnosis invasive procedure, 120
neural tube defects (NTD), 119
trimester screening test, 119
President’s Emergency Plan for AIDS Relief (PEPFAR), 289–290
Prevention and control, African-Americans antiretroviral therapy, 2
diagnosis and treatment, 13–14
drug use, prevalence
diversity, 228
sexual behavior, 228–229
effective preventive interventions, 14
health care, 16
highly active antiretroviral therapy (HAART), 5
HIV risk reduction strategies, drug using population
accessible treatment and services, mental health issues, 236
benefits, social support, 236–237
community-based outreach, 233
drug treatment, 233–234
network-based interventions, 234–235
integrated treatment, dual and triple diagnosis
ancillary services, 239
mental health and substance abuse, 238
model, 238–239
multiple service delivery system, 237–238
mental disorder prevalence, 229
mental illness, HIV treatment, 231–232
protease inhibitors, 2
social determinants
broader community action
mobilization, 15
coordination and collaboration, 17
National leadership, 16
research and education, 16–17
socioeconomic status, 8, 9
unemployment and underemployment, 8
substance abuse
definition, 235
multiple factors, 230
syndemic theory, 230–231
Prevention of mother to child transmission, 291, 294
Primary Care Case Management (PCCM) system, 266
Public Health Service (PHS), 109, 111
Race/ethnicity effect
clinical trials
HIV treatment, 43
virologic failure, efavirenz-based therapy, 44
cohort studies, 42–43
Raltegravir, 46
Renal replacement therapy (RRT), 170
Risk and prevention analysis
gender-specific intervention, 219
gender-tailored intervention, 220
generalized estimating equations (GEE) analysis, 222
HIV-related exposures and risk factors, 218
HIV risk reduction agenda, 224–225
multiple logistic regression analysis, 220–221
Ritonavir-boosted protease inhibitor advantages and disadvantages, 38
atazanavir (ATV/r), 37
boosted lopinavir (LVP/r), 37
cytochrome p-450 cyp3A4 enzyme, 36
Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, 72
Ryan White HIV/AIDS program autonomy, 271–272
benefits, 272
clinical and technical training, 273
community and consumer involvement, 272–273
funds, 273–274
limitation, 274
Minority AIDS Initiative (MAI), 273
summary, 271
SCID. See Structured Clinical Interview for DSM-IV Disorders
SEP. See Syringe exchange program
Sexually transmitted diseases, 85–86
Sexually transmitted infections (STI), 10
non-ulcerative
bacterial vaginosis, 89
gonorrhea and chlamydia, 90
trichomonas vaginalis, 89
ulcerative
genital ulcer disease, 85
syphilis, 85, 90
SHAS. See Supplement to HIV and AIDS Surveillance Project
Sistas, informing healing, living and empowering (SIHLE)
design and implementation, 222
evidence-based HIV intervention, 223–224
Slave medicine, 248–249
Social health of African-American women (SHAWL), 214
Social security disability insurance (SSDI) program, 270
Staphylococcus aureus
gram-positive bacterial pathogen, 135
methicillin-resistant (MRSA) infection, 135
nasal colonization, 136
STI. See Sexually transmitted infections
Strategies for the management of anti-retroviral therapy (SMART), 166
Structured Clinical Interview for DSM-IV Disorders, 229
 Substance abuse, 10
 definition, 235
drug effects on brain, 230
drug use, prevalence
diversity, 228
injection drug, 228
sexual behavior, 228–229
multiple factors, 230
syndemic theory, 230–231
Supplemental security income (SSI) program, 264
Supplement to HIV and AIDS Surveillance Project
black participants, 254
HIV-infected subjects, 245
poverty, participant, 253
Syphilis
 chancre, primary stage, 136–137
civil rights, 251
condylomata lata, 137, 139
copper-colored papules on the sole, 140
emtricitabine (FTC), 138
erythematous scaly papules, 137–138
genital ulcer disease, 140
and HIV, 140–141
palmoplantar hyperpigmentation, 140
racial discrimination and exploitation, 250
scaly red-brown papules on the palms, 139
 spirochete Treponema palladium, 136
Syringe exchange program (SEP), 234
Temporary assistance to needy families (TANF) program, 264
Thrombocytopenia, 88
Tool for assessing cultural competence training (TACCT), 76
Transgender women, HIV prevention
 health care, 194
risk behavior, 193
seroprevalence rate, 194
unprotected receptive anal intercourse (URAI), 193
Unified global HIV prevalence
 acceptability, HIV testing, 294–295
adult 15–49 prevalence, 285
antiretroviral therapy
 adherence, 291–292
scale-up, 290
Caribbean
 Cuba, 287–288
epidemic spread, 286–287
Haiti, 287
Puerto Rico, 288
condom use, 293
health care settings, 295
HIV infection, 283
international treatment program, 294
Latin America
 Belize, 288–289
Brazil, 288
Mexico, 289
male circumcision
decreased HIV transmission risk, 285–286
dissemination challenges, 293
National prevention strategy
cultural and sexual behavioral norms, 292
Uganda, 292
opt-out testing, 294–295
resource limited settings, 291
sub-Saharan Africa
behavioral factors, 286
Eastern Africa, 284–285
gender based disparities, 284
genital herpes simplex virus infection-2 (HSV), 286
geography, 284
HIV rates, 284
Western and Central Africa, 285
treatment and challenges
funding, 289
human resources, 290–291
prevention of mother to child transmission (PMTCT), 291
tuberculosis (TB) coinfection, 290–291
universal access, 283
vaccine development, 295
US Department of Health and Human Services, 70
US minority patients
care and treatment, 59–60
clinical staff diversification, 59
communication enhancement, 58–59
cultural and social context, 56–57
disproportionate rate, HIV infection, 54
health care, 56
highly active antiretroviral therapy (HAART), 53
mortality rate, 54, 55
patient engagement enhancement, 59–60
patient–provider relationship, 59, 60
Verrucous papules, 137. See also
 Condylomata lata
Veterans administration (VA) system, 162
Viral resistance to antiviral therapy of chronic hepatitis C (VIRAHEP-C), 164
Warts, 144–145. See also Human papilloma virus infection

Weight-based dosing of peg-intron and rebetrol trial (WIN-R trial), 164

Women involved in life learning from other women (WILLOW)
  evidence-based HIV intervention, 223
  randomized controlled trial, 221

Women’s Interagency HIV Study (WIHS), 253

Xerosis
  dry skin, 149–150
  dyshidrotic eczema, 150
  nummular eczema, 150

Zidovudine
  immediate vs. delayed therapy, 246
  lamivudine combination, 40